Characterization of mRNA therapeutics
The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.
Abstract
Therapeutic messenger RNAs (mRNAs) have emerged as powerful tools in the treatment of complex diseases, especially for conditions that lack efficacious treatment. The successful application of this modality can be attributed to its ability to encode entire proteins. While the large nature of these molecules has supported their success as therapeutics, its extended size creates several analytical challenges. To further support therapeutic mRNA development and its deployment in clinical trials, appropriate methods to support their characterization must be developed. In this review, we describe current analytical methods that have been used in the characterization of RNA quality, identity, and integrity. Advantages and limitations from several analytical techniques ranging from gel electrophoresis to liquid chromatography–mass spectrometry and from shotgun sequencing to intact mass measurements are discussed. We comprehensively describe the application of analytical methods in the measurements of capping efficiency, poly A tail analysis, as well as their applicability in stability studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Although it is a sensitive and high-resolution method, the analysis of long mRNA can be challenging due to multiply charged states and associated spectral complexity.21,46”
From Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses (2024) · cites this paper as [21]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The RIN: an RNA integrity number for assigning integrity values to RNA measurements
Schroeder, A., Mueller, O., Stocker, S., Salowsky, R., Leiber, M., Gassmann, M., Lightfoot, S., Menzel, W., Granzow, M., & Ragg, T. (2006) · BMC Molecular Biology · doi:10.1186/1471-2199-7-3 · Cited by 2,623
mRNA-based therapeutics--developing a new class of drugs
Sahin, U., Karikó, K., & Türeci, Ö. (2014) · Nature Reviews Drug Discovery · doi:10.1038/nrd4278 · Cited by 2,474
RIG-I-mediated antiviral responses to single-stranded RNA bearing 5’-phosphates
Pichlmair, A., Schulz, O., Tan, C. P., Näslund, T. I., Liljeström, P., Weber, F., & Reis e Sousa, C. (2006) · Science · doi:10.1126/science.1132998 · Cited by 2,210
The Architecture of SARS-CoV-2 Transcriptome
Kim, D., Lee, J.-Y., Yang, J.-S., Kim, J. W., Kim, V. N., & Chang, H. (2020) · Cell · doi:10.1016/j.cell.2020.04.011 · Cited by 2,123
Self-citationKarikó, K., Muramatsu, H., Welsh, F. A., Ludwig, J., Kato, H., Akira, S., & Weissman, D. (2008) · Molecular Therapy · doi:10.1038/mt.2008.200 · Cited by 1,930
mRNA-lipid nanoparticle COVID-19 vaccines: structure and stability
Schoenmaker, L., Witzigmann, D., Kulkarni, J. A., Verbeke, R., Kersten, G., Jiskoot, W., & Crommelin, D. J. A. (2021) · International Journal of Pharmaceutics · doi:10.1016/j.ijpharm.2021.120586 · Cited by 1,566
At least six nucleotides preceding the AUG initiator codon enhance translation in mammalian cells
Kozak, M. (1987) · Journal of Molecular Biology · doi:10.1016/0022-2836(87)90418-9 · Cited by 1,182
Karikó, K., Muramatsu, H., Ludwig, J., & Weissman, D. (2011) · Nucleic Acids Research · doi:10.1093/nar/gkr695 · Cited by 898
Codon optimality, bias and usage in translation and mRNA decay
Hanson, G., & Coller, J. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.91 · Cited by 825
Taylor, S. C., Laperriere, G., & Germain, H. (2017) · Scientific Reports · doi:10.1038/s41598-017-02217-x · Cited by 638
A facile method for the removal of dsRNA contaminant from in vitro-transcribed mRNA
Baiersdörfer, M., Boros, G., Muramatsu, H., Mahiny, A., Vlatkovic, I., Sahin, U., & Karikó, K. (2019) · Molecular Therapy — Nucleic Acids · doi:10.1016/j.omtn.2019.02.018 · Cited by 569
mRNA vaccines manufacturing: challenges and bottlenecks
Rosa, S. S., Prazeres, D. M. F., Azevedo, A. M., & Marques, M. P. C. (2021) · Vaccine · doi:10.1016/j.vaccine.2021.03.038 · Cited by 545
Addressing the Cold Reality of mRNA Vaccine Stability
Crommelin, D. J. A., Anchordoquy, T. J., Volkin, D. B., Jiskoot, W., & Mastrobattista, E. (2021) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2020.12.006 · Cited by 517
Multifunctional deadenylase complexes diversify mRNA control
Goldstrohm, A. C., & Wickens, M. (2008) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm2370 · Cited by 377
Challenges of Storage and Stability of mRNA-Based COVID-19 Vaccines
Uddin, M. N., & Roni, M. A. (2021) · Vaccines · doi:10.3390/vaccines9091033 · Cited by 371
Kim, S. C., Sekhon, S. S., Shin, W.-R., Ahn, G., Cho, B.-K., Ahn, J.-Y., & Kim, Y.-H. (2022) · Molecular & Cellular Toxicology · doi:10.1007/s13273-021-00171-4 · Cited by 255
Cap 1 Messenger RNA Synthesis with Co‐transcriptional CleanCap ® Analog by In Vitro Transcription
Henderson, J. M., Ujita, A., Hill, E., Yousif‐Rosales, S., Smith, C., Ko, N., McReynolds, T., Cabral, C. R., Escamilla‐Powers, J. R., & Houston, M. E. (2021) · Current Protocols · doi:10.1002/cpz1.39 · Cited by 231
Weissman, D. (2015) · Expert Review of Vaccines · doi:10.1586/14760584.2015.973859 · Cited by 228
Kwon, H., Kim, M., Seo, Y., Moon, Y. S., Lee, H. J., Lee, K., & Lee, H. (2018) · Biomaterials · doi:10.1016/j.biomaterials.2017.11.034 · Cited by 208
Detailed Dissection and Critical Evaluation of the Pfizer/BioNTech and Moderna mRNA Vaccines
Xia, X. (2021) · Vaccines · doi:10.3390/vaccines9070734 · Cited by 201
Kafader, J. O., Melani, R. D., Durbin, K. R., Ikwuagwu, B., Early, B. P., Fellers, R. T., Beu, S. C., Zabrouskov, V., Makarov, A. A., Maze, J. T., et al. (2020) · Nature Methods · doi:10.1038/s41592-020-0764-5 · Cited by 197
Review of COVID-19 mRNA Vaccines: BNT162b2 and mRNA-1273
Teo, S. P. (2022) · Journal of Pharmacy Practice · doi:10.1177/08971900211009650 · Cited by 191
Wörner, T. P., Snijder, J., Bennett, A., Agbandje-McKenna, M., Makarov, A. A., & Heck, A. J. R. (2020) · Nature Methods · doi:10.1038/s41592-020-0770-7 · Cited by 186
HPLC purification of in vitro transcribed long RNA
Weissman, D., Pardi, N., Muramatsu, H., & Karikó, K. (2013) · Methods in molecular biology · doi:10.1007/978-1-62703-260-5_3 · Cited by 180
Trepotec, Z., Geiger, J., Plank, C., Aneja, M. K., & Rudolph, C. (2019) · RNA · doi:10.1261/rna.069286.118 · Cited by 129
Long-term storage of DNA-free RNA for use in vaccine studies
Jones, K. L., Drane, D., & Gowans, E. J. (2007) · BioTechniques · doi:10.2144/000112593 · Cited by 115
Harper, C. C., Elliott, A. G., Oltrogge, L. M., Savage, D. F., & Williams, E. R. (2019) · Analytical Chemistry · doi:10.1021/acs.analchem.9b01669 · Cited by 84
Label-free analysis of mRNA capping efficiency using RNase H probes and LC-MS
Beverly, M., Dell, A., Parmar, P., & Houghton, L. (2016) · Analytical and Bioanalytical Chemistry · doi:10.1007/s00216-016-9605-x · Cited by 83
Research works printed but not linked: 117
- 10.1038/mt.2012.29 · DOI · Paper page
- 10.1093/nar/29.2.e7 · DOI
- 10.7554/eLife.76562 · DOI
- 10.1002/(SICI)1096-9888(199611)31:11<1277::AID-JMS418>3.0.CO;2-F · doi:10.1002/(sici)1096-9888(199611)31:11<1277::aid-jms418>3.0.co;2-f
- 10.4155/bio.14.94 · DOI
- 10.1007/s13361-016-1500-3 · doi:10.1007/s13361-016-1500-3
- 10.1038/s41598-018-27570-3 · DOI
- 10.1021/ac970163e · DOI · Paper page
- 10.1007/s00216-017-0840-6 · DOI
- Bilska A, 2022, Measuring the tail: Methods for poly (A) tail profiling, e1737
- 10.1016/j.jphotobiol.2013.09.010 · DOI
- Brophy P, 2022, Characterization of intact mRNA using IP‐RP‐TOF‐MS, SEC MALS and CDMS, ASMS Conference, TP405
- 10.1038/nbt.3622 · DOI
- 10.1021/ja00096a046 · DOI · Paper page
- 10.1016/j.chroma.2013.03.003 · doi:10.1016/j.chroma.2013.03.003
- 10.1021/ac00103a004 · DOI
- 10.1093/nar/24.11.2183 · doi:10.1093/nar/24.11.2183
- 10.1016/j.chroma.2016.02.057 · doi:10.1016/j.chroma.2016.02.057
- 10.1021/acs.analchem.2c03030 · DOI
- Currie J, 2021, Stability indicating ion‐pair reversed‐phase liquid chromatography method for modified mRNA, ChemRxiv
- 10.1038/s41467-022-30057-5 · DOI
- 10.1093/nar/gkac414 · DOI
- 10.1016/j.chroma.2018.05.048 · DOI
- 10.1016/j.chroma.2021.462283 · DOI
- 10.1002/mas.21798 · DOI
- 10.1016/j.chroma.2022.462860 · DOI
- 10.1002/bmc.4088 · DOI
- 10.1021/ac00179a722 · doi:10.1021/ac00179a722
- 10.1021/acs.analchem.1c05466 · doi:10.1021/acs.analchem.1c05466
- 10.1016/j.jcoa.2022.100031 · DOI
- 10.1021/acscentsci.1c00788 · DOI
- Foreman D, 2022, Negative mode charge detection mass spectrometry: mass determination of intact mRNA, ASMS Conference, 8, 50
- 10.1002/rcm.1290091513 · DOI · Paper page
- 10.1186/s13059-020-02241-7 · DOI · Paper page
- 10.1038/nmeth.4577 · DOI · Paper page
- 10.1016/S0021-9673(99)01178-4 · doi:10.1016/s0021-9673(99)01178-4
- 10.1016/j.omtm.2022.03.009 · DOI · Paper page
- 10.1016/j.jpba.2021.114439 · doi:10.1016/j.jpba.2021.114439
- 10.1021/ac990160x · doi:10.1021/ac990160x
- 10.1186/1471-2229-13-119 · DOI
- 10.1186/s13059-021-02557-y · DOI
- 10.1021/ac00099a015 · doi:10.1021/ac00099a015
- 10.1093/nar/gni054 · DOI · Paper page
- 10.1038/s41592-022-01633-w · DOI · Paper page
- 10.1261/rna.031898.111 · DOI · Paper page
- 10.1021/acs.chemrev.1c00377 · DOI
- 10.3390/vaccines9090965 · DOI
- 10.1021/acs.analchem.9b01664 · DOI
- 10.1128/MCB.26.6.2419-2429.2006 · DOI
- 10.1126/science.1225829 · DOI · Paper page
- 10.1038/s41598-018-37642-z · DOI
- 10.1038/nature04734 · DOI · Paper page
- 10.1002/jms.4465 · DOI
- 10.1016/j.omtn.2019.07.006 · DOI
- 10.1016/j.jchromb.2022.123168 · doi:10.1016/j.jchromb.2022.123168
- 10.1111/dgd.12608 · DOI · Paper page
- 10.1016/0092-8674(78)90150-2 · DOI
- 10.1021/acs.analchem.2c04114 · DOI
- 10.1038/s41467-021-27393-3 · DOI · Paper page
- Liau B, 2021, Rapid Analysis of mRNA 5′ capping with high‐resolution LC/MS
- 10.1002/(SICI)1098-2787(1996)15:5<297::AID-MAS2>3.0.CO;2-D · DOI
- 10.1002/wrna.1367 · DOI
- 10.1016/j.ymeth.2018.10.012 · DOI
- 10.1016/j.chroma.2020.460875 · DOI
- 10.1261/rna.5264804 · DOI · Paper page
- 10.1021/ja00078a054 · doi:10.1021/ja00078a054
- 10.1016/1044-0305(92)85019-G · DOI · Paper page
- 10.4161/rna.27992 · DOI
- Morreel K, 2022, Diving into the structural details of in vitro transcribed mRNA using liquid chromatography–mass spectrometry‐based oligonucleotide profiling. LCGC, Europe, 35, 220
- 10.1016/j.aca.2021.338987 · DOI
- 10.1093/nar/gkp099 · DOI
- 10.32607/20758251-2011-3-2-22-33 · DOI
- 10.1038/s41592-022-01513-3 · DOI
- 10.1021/ac960270t · DOI · Paper page
- 10.1021/ja00035a012 · DOI · Paper page
- 10.1007/s13361-012-0529-1 · doi:10.1007/s13361-012-0529-1
- 10.1021/ac015595a · doi:10.1021/ac015595a
- 10.1002/rcm.8927 · DOI
- 10.1038/s41467-021-26926-0 · DOI · Paper page
- 10.7554/eLife.49658 · DOI · Paper page
- 10.1002/(SICI)1520-6017(200004)89:4<443::AID-JPS2>3.0.CO;2-W · DOI
- 10.1002/rcm.338 · doi:10.1002/rcm.338
- 10.1038/s41392-022-01007-w · DOI · Paper page
- 10.1016/j.cancergen.2020.02.007 · DOI
- 10.1002/jms.3207 · DOI
- 10.1002/elps.202100272 · DOI
- 10.1093/nar/gkw551 · DOI · Paper page
- 10.1101/pdb.prot5445 · doi:10.1101/pdb.prot5445
- 10.1002/elps.11501301102 · DOI
- 10.1261/rna.049429.114 · DOI
- 10.1016/S1044-0305(01)00354-3 · doi:10.1016/s1044-0305(01)00354-3
- 10.1006/meth.1998.0705 · DOI · Paper page
- 10.1073/pnas.74.12.5463 · DOI · Paper page
- Schneeberger E, 2021, Expanding the Horizon: LC‐MS approaches for intact mass spectrometry of pharmaceutical mRNA up to 2000‐nt long, ASMS Conference, 2, 30
- 10.1002/elps.1150170917 · DOI
- 10.1002/cpmb.59 · DOI · Paper page
- SmithAM JainM MulroneyL GaraldeDR andAkesonM.Reading canonical and modified nucleotides in 16S ribosomal RNA using nanopore direct RNA sequencing. bioRxiv.2017:132274. · DOI
- 10.1021/acsomega.2c00185 · DOI
- 10.1002/elps.200800457 · DOI
- 10.1002/mas.21641 · DOI
- TavakoliS NabizadehmashhadtoroghiM MakhamrehA GamperH McCormickCA RezapourNK HouY‐M WanunuM andRouhanifardSH.Semi‐quantitative detection of pseudouridine modifications and type I/II hypermodifications in human mRNAs using direct and long‐read sequencing. bioRxiv.2022:2021.2011.2003.467190.
- Technologies A, 2020, Comparison of RIN and RQN for the Agilent 2100 bioanalyzer and fragment analyzer systems, Application Note, 5994
- 10.1002/1522-2683(200107)22:12<2442::AID-ELPS2442>3.0.CO;2-9 · doi:10.1002/1522-2683(200107)22:12<2442::aid-elps2442>3.0.co;2-9
- 10.1016/j.yexcr.2014.01.008 · DOI · Paper page
- 10.1021/acs.analchem.2c00765 · DOI
- 10.1101/gr.247064.118 · DOI · Paper page
- Wang P, 2022, SEC‐MALS Method for Characterizing mRNA Biophysical Attributes
- 10.1016/j.chroma.2022.462839 · DOI
- 10.1038/s41467-020-14665-7 · DOI
- 10.2144/97223st01 · DOI · Paper page
- 10.1093/nar/gkac632 · DOI
- 10.3389/fmicb.2019.00260 · DOI
- 10.1261/rna.073858.119 · DOI · Paper page
- 10.1016/j.chroma.2013.09.021 · doi:10.1016/j.chroma.2013.09.021
- 10.1016/0076-6879(89)80090-4 · DOI
- 10.1021/acs.analchem.7b01780 · DOI
- 10.3390/ijms23052736 · DOI · Paper page
Cited by
Exploring the Impact of In Vitro-Transcribed mRNA Impurities on Cellular Responses
Camperi, J., Roper, B., Freund, E., Leylek, R., Nissenbaum, A., Galan, C., Caothien, R., Hu, Z., Ko, P., Lee, A., et al. (2024) · Analytical Chemistry · doi:10.1021/acs.analchem.4c04162 · Cited by 22
Metadata
- Authors
- Guimaraes, G. J., Kim, J., & Bartlett, M. G.
- Venue
- Mass Spectrometry Reviews
- Publisher
- Wiley
- Published
- 2023-07-04
- Volume
- 43
- Issue
- 5
- Pages
- 1066-1090
- ISSN
- 0277-7037
- 1098-2787
- Cited by
- 44
- References
- 28
- Language
- en
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.